-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA Accepts Priority Review Of Biologics License Application For ltragenyx Pharmaceutical's DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia

Benzinga·02/23/2026 13:34:07
Listen to the news

If approved, DTX401 will be the first treatment to address the underlying cause of GDSIa